Genetic Variants in C5 and Poor Response to Eculizuma

New England Journal of Medicine
370, 632-639
DOI: 10.1056/nejmoa1311084

Citation Report

#	Article	IF	Citations
1	Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology, 2014, 7, 583-598.	1.0	43
2	Control of innate immunological mechanisms as a route to drug minimization. Current Opinion in Organ Transplantation, 2014, 19, 342-347.	0.8	5
3	Report of the Inefficacy of Eculizumab in Two Cases of Severe Antibody-Mediated Rejection of Renal Grafts. Transplantation, 2014, 98, 1056-1059.	0.5	61
4	Syndromes of Thrombotic Microangiopathy. New England Journal of Medicine, 2014, 371, 654-666.	13.9	972
5	Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria. Pediatric Blood and Cancer, 2014, 61, 1544-1550.	0.8	35
8	Paroxysmal nocturnal hemoglobinuria. Blood, 2014, 124, 2804-2811.	0.6	424
9	Mutations in C5 explain eculizumab resistance. Nature Reviews Nephrology, 2014, 10, 182-182.	4.1	7
10	Complement in hemolytic anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 385-391.	0.9	9
11	Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the <scp>A</scp>ustralian compassionate access cohort. Internal Medicine Journal, 2015, 45, 1054-1065.	0.5	25
12	Complement inhibition for paroxysmal nocturnal hemoglobinuria: where we stand and where we are going. Expert Opinion on Orphan Drugs, 2015, 3, 691-704.	0.5	2
13	Complement in hemolytic anemia. Blood, 2015, 126, 2459-2465.	0.6	84
14	Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood, 2015, 125, 775-783.	0.6	122
16	Complement activation, regulation, and molecular basis for complementâ€related diseases. EMBO Journal, 2015, 34, 2735-2757.	3.5	302
17	Laboratory tests for disorders of complement and complement regulatory proteins. American Journal of Hematology, 2015, 90, 1180-1186.	2.0	18
18	Paroxysmal nocturnal hemoglobinuria: new concepts in pathophysiology and treatment. Orphan Drugs: Research and Reviews, 2015, , 75.	0.6	1
19	Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group. Medicina ClÃnica (English Edition), 2015, 144, 331.e1-331.e13.	0.1	2
21	Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria. Blood Cells, Molecules, and Diseases, 2015, 54, 144-150.	0.6	18
22	Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway. Journal of the American Society of Nephrology: JASN, 2015, 26, 2917-2929.	3.0	84

#	Article	IF	Citations
23	Paroxysmal Nocturnal Hemoglobinuria. Hematology/Oncology Clinics of North America, 2015, 29, 479-494.	0.9	52
24	Paroxysmal nocturnal hemoglobinuria revisited: news on pathophysiology, clinical course and treatment. Laboratoriums Medizin, 2015, 39, 87-96.	0.1	0
25	Oxidative stress in paroxysmal nocturnal hemoglobinuria and other conditions of complement-mediated hemolysis. Free Radical Biology and Medicine, 2015, 88, 63-69.	1.3	15
26	Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America, 2015, 29, 541-559.	0.9	25
27	Current and Future Pharmacologic Complement Inhibitors. Hematology/Oncology Clinics of North America, 2015, 29, 561-582.	0.9	30
28	Complement, a target for therapy in inflammatory and degenerative diseases. Nature Reviews Drug Discovery, 2015, 14, 857-877.	21.5	357
29	Applying complement therapeutics to rare diseases. Clinical Immunology, 2015, 161, 225-240.	1.4	60
30	Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. MAbs, 2015, 7, 1205-1211.	2.6	67
31	Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Translational Research, 2015, 165, 306-320.	2.2	64
32	Eculizumabâ˜†. , 2016, , .		0
33	Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. World Journal of Nephrology, 2016, 5, 308.	0.8	16
34	Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria. F1000Research, 2016, 5, 209.	0.8	38
35	Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern. Case Reports in Nephrology, 2016, 2016, 1-7.	0.2	2
36	Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. Journal of Blood Medicine, 2016, 7, 39.	0.7	20
37	Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria. International Journal of Laboratory Hematology, 2016, 38, e84-5.	0.7	4
38	Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition. American Journal of Hematology, 2016, 91, 359-360.	2.0	4
39	From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology, 2016, 221, 1046-1057.	0.8	14
40	Complement inhibition as potential new therapy for antibody-mediated rejection. Transplant International, 2016, 29, 392-402.	0.8	28

#	Article	IF	Citations
41	Stratification of responders towards eculizumab using a structural epitope mapping strategy. Scientific Reports, 2016, 6, 31365.	1.6	16
42	Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. Hematology American Society of Hematology Education Program, 2016, 2016, 208-216.	0.9	85
43	Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action. Molecular Immunology, 2016, 77, 126-131.	1.0	21
44	Eculizumab Dosing Intervals Longer than 17 Days May Be Associated with Greater Risk of Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria. Biological and Pharmaceutical Bulletin, 2016, 39, 285-288.	0.6	38
45	Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. , 2016, , 531-547.		0
46	PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro. Bioconjugate Chemistry, 2016, 27, 2359-2371.	1.8	53
47	Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 1092-1096.	1.3	15
48	Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. Immunobiology, 2016, 221, 1247-1258.	0.8	77
49	Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Advances in Clinical Chemistry, 2016, 77, 1-75.	1.8	36
50	Structural insight into proteolytic activation and regulation of the complement system. Immunological Reviews, 2016, 274, 59-73.	2.8	50
51	All Things Complement. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1856-1866.	2.2	61
52	New milestones ahead in complement-targeted therapy. Seminars in Immunology, 2016, 28, 208-222.	2.7	92
53	Targeting the complement cascade: novel treatments coming down the pike. Kidney International, 2016, 90, 746-752.	2.6	41
54	Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway. Journal of Immunology, 2016, 197, 337-344.	0.4	76
55	Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future. Seminars in Immunology, 2016, 28, 223-240.	2.7	36
56	Emerging Therapies in Antiphospholipid Syndrome. Current Rheumatology Reports, 2016, 18, 22.	2.1	37
57	Complement therapeutics in inflammatory diseases: promising drug candidates for C3â€targeted intervention. Molecular Oral Microbiology, 2016, 31, 3-17.	1.3	36
58	Structural basis for therapeutic inhibition of complement C5. Nature Structural and Molecular Biology, 2016, 23, 378-386.	3.6	94

#	Article	IF	Citations
59	Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology, 2016, 221, 503-511.	0.8	28
60	Unmanipulated haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with paroxysmal nocturnal hemoglobinuria and secondary aplastic anemia. Bone Marrow Transplantation, 2016, 51, 316-318.	1.3	4
61	Haploidentical hematopoietic stem cell transplant in paroxysmal nocturnal hemoglobinuria. Leukemia and Lymphoma, 2016, 57, 835-841.	0.6	20
62	The genetics of drug efficacy: opportunities and challenges. Nature Reviews Genetics, 2016, 17, 197-206.	7.7	93
63	Liver transplantation for aHUS: still needed in the eculizumab era?. Pediatric Nephrology, 2016, 31, 759-768.	0.9	22
64	Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clinical and Experimental Nephrology, 2016, 20, 265-272.	0.7	22
65	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatric Nephrology, 2016, 31, 15-39.	0.9	445
66	Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology, 2016, 221, 715-718.	0.8	6
67	A national specialized service in England for atypical haemolytic uraemic syndromeâ€"the first yearâ€™s experience. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 27-33.	0.2	82
68	Paroxysmal Nocturnal Hemoglobinuria. , 2017, , .		1
69	Complementopathies. Blood Reviews, 2017, 31, 213-223.	2.8	86
70	Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends in Immunology, 2017, 38, 383-394.	2.9	31
71	Eculizumab for the treatment of hemolytic paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and refractory myasthenia gravis. Expert Opinion on Orphan Drugs, 2017, 5, 375-379.	0.5	1
72	Paroxysmal nocturnal haemoglobinuria. Nature Reviews Disease Primers, 2017, 3, 17028.	18.1	299
73	Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrology Dialysis Transplantation, 2017, 32, i57-i64.	0.4	13
74	Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndromeâ€"Biomarkers of the Disease and Biopharmaceuticals. Current Rheumatology Reports, 2017, 19, 40.	2.1	4
75	Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Molecular Immunology, 2017, 89, 10-21.	1.0	79
76	New concepts on the therapeutic control of complement anaphylatoxin receptors. Molecular Immunology, 2017, 89, 36-43.	1.0	67

#	Article	IF	Citations
77	At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature. Therapeutic Apheresis and Dialysis, 2017, 21, 304-319.	0.4	5
78	Kidney Diseases Associated With Alternative Complement Pathway Dysregulation and Potential Treatment Options. American Journal of the Medical Sciences, 2017, 354, 533-538.	0.4	8
80	Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood, 2017, 129, 970-980.	0.6	119
81	Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica, 2017, 102, 466-475.	1.7	74
82	Thrombotic Microangiopathy in Inverted Formin 2â€“Mediated Renal Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 1084-1091.	3.0	42
83	Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlyingÂgenetic disorders. Kidney International, 2017, 92, 1493-1506.	2.6	74
84	Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses. Molecular Immunology, 2017, 89, 111-114.	1.0	17
85	Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Scientific Reports, 2017, 7, 1080.	1.6	79
86	Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes. Journal of Hematology and Oncology, 2017, 10, 126.	6.9	28
87	Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2017, 15, 312-322.	1.9	362
88	Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders. Clinical and Experimental Immunology, 2017, 187, 304-315.	1.1	76
89	Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment. Immunobiology, 2017, 222, 363-371.	0.8	13
90	Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Advances, 2017, 1, 1254-1258.	2.5	32
91	Anti-complement component 5 antibody targeting MG4 domain inhibits choroidal neovascularization. Oncotarget, 2017, 8, 45506-45516.	0.8	9
92	Renal involvement in paroxysmal nocturnal hemoglobinuria: an update on clinical features, pathophysiology and treatment. Hematology, 2018, 23, 558-566.	0.7	28
93	Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome. Seminars in Hematology, 2018, 55, 150-158.	1.8	39
94	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Internal Medicine Journal, 2018, 48, 624-636.	0.5	26
95	Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology, 2018, 55, 124-129.	1.8	19

#	Article	IF	Citations
96	Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology, 2018, 55, 167-175.	1.8	32
97	The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential. Journal of the American Society of Nephrology: JASN, 2018, 29, 1141-1153.	3.0	28
98	Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Nephrology, 2018, 23, 507-517.	0.7	21
99	Acetylcholine receptor antibodyâ€“mediated animal models of myasthenia gravis and the role of complement. Annals of the New York Academy of Sciences, 2018, 1413, 136-142.	1.8	13
100	Glucose-6-Phosphate Dehydrogenase Deficiency Mimicking Atypical Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2018, 71, 287-290.	2.1	4
101	Diseases of complement dysregulationâ€”an overview. Seminars in Immunopathology, 2018, 40, 49-64.	2.8	83
102	Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 2018, 93, 564-577.	2.0	45
103	Treatment of Myasthenia Gravis. , 2018, , 169-187.		4
104	Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology. Clinical and Experimental Nephrology, 2018, 22, 3-14.	0.7	36
105	Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLoS ONE, 2018, 13, e0209509.	1.1	38
106	Immunophysical Evaluation of the Initiating Step in the Formation of the Membrane Attack Complex. Frontiers in Physics, 2018, 6, .	1.0	4
107	Haplosaurus computes protein haplotypes for use in precision drug design. Nature Communications, 2018, 9, 4128.	5.8	21
108	Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation. Journal of Korean Medical Science, 2018, 33, e4.	1.1	4
109	Therapeutic complement modulation for hematological diseases: Where we stand and where we are going. Seminars in Hematology, 2018, 55, 113-117.	1.8	1
110	C5. , 2018, , 187-201.		1
111	The impact of eculizumab on routine complement assays. Journal of Immunological Methods, 2018, 460, 63-71.	0.6	22
112	Advances in autoimmune myasthenia gravis management. Expert Review of Neurotherapeutics, 2018, 18, 573-588.	1.4	40
113	Paroxysmal Nocturnal Hemoglobinuria. , 2018, , 415-424.		1

#	Article	IF	Citations
114	Complement and Immunoglobulin Biology Leading to Clinical Translation. , 2018, , 261-284.e6.		0
115	The rational design of affinity-attenuated OmCI for the purification of complement C5. Journal of Biological Chemistry, 2018, 293, 14112-14121.	1.6	13
117	Developments in anti-complement therapy; from disease to clinical trial. Molecular Immunology, 2018, 102, 89-119.	1.0	72
118	C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications. Seminars in Hematology, 2018, 55, 130-135.	1.8	25
119	Novel Approaches to Block Complement. Transplantation, 2018, 102, 1837-1843.	0.5	12
120	Common and rare genetic variants of complement components in human disease. Molecular Immunology, 2018, 102, 42-57.	1.0	18
121	Safety and effectiveness of eculizumab for pediatric patients with atypical hemolyticâ€“uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clinical and Experimental Nephrology, 2019, 23, 112-121.	0.7	31
122	Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients. Frontiers in Immunology, 2019, 10, 1639.	2.2	17
123	Myasthenia gravis and specific immunotherapy: monoclonal antibodies. Annals of the New York Academy of Sciences, 2019, 1452, 18-33.	1.8	8
124	Targeting the complement system in bacterial meningitis. Brain, 2019, 142, 3325-3337.	3.7	36
126	Clinical promise of next-generation complement therapeutics. Nature Reviews Drug Discovery, 2019, 18, 707-729.	21.5	253
127	Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Frontiers in Immunology, 2019, 10, 1157.	2.2	133
128	Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfusion Medicine Reviews, 2019, 33, 256-265.	0.9	46
130	Complement Inhibitors in Clinical Trials for Glomerular Diseases. Frontiers in Immunology, 2019, 10, 2166.	2.2	86
131	Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Therapeutic Advances in Hematology, 2019, 10, 204062071987472.	1.1	50
132	Novel insights into the treatment of complement-mediated hemolytic anemias. Therapeutic Advances in Hematology, 2019, 10, 204062071987332.	1.1	65
133	A small-molecule inhibitor of C5 complement protein. Nature Chemical Biology, 2019, 15, 666-668.	3.9	17
134	Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Molecular Therapy - Methods and Clinical Development, 2019, 13, 484-492.	1.8	37

#	Article	IF	Citations
135	Isolated Liver Transplantation: A Worthy Choice for Atypical Hemolytic Syndrome inÂResource-Restricted Settings. Kidney International Reports, 2019, 4, 1019-1022.	0.4	0
136	Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2018. Leukemia Research, 2019, 80, 19-25.	0.4	1
137	An LCâ€“MS/MS approach to assess total and free protein target in the serum of cynomolgus monkey. Bioanalysis, 2019, 11, 393-406.	0.6	4
138	Hemolytic Uremic Syndrome, Genetic. , 2019, , 667-679.		0
139	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clinical Pharmacokinetics, 2019, 58, 859-874.	1.6	82
140	Induction of Accommodation by Antiâ€“complement Component 5 Antibody-based Immunosuppression in ABO-incompatible Heart Transplantation. Transplantation, 2019, 103, e248-e255.	0.5	8
141	Current and Future Approaches for Monitoring Responses to Anti-complement Therapeutics. Frontiers in Immunology, 2019, 10, 2539.	2.2	13
142	Emerging immunotherapies for autoimmune kidney disease. Human Vaccines and Immunotherapeutics, 2019, 15, 876-890.	1.4	3
143	Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatric Nephrology, 2019, 34, 2261-2277.	0.9	60
144	Pathogenesis of Atypical Hemolytic Uremic Syndrome. Journal of Atherosclerosis and Thrombosis, 2019, 26, 99-110.	0.9	53
145	Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood, 2019, 133, 530-539.	0.6	227
146	DownstreamTRPM4Polymorphisms Are Associated with Intracranial Hypertension and Statistically Interact withABCC8Polymorphisms in a Prospective Cohort of Severe Traumatic Brain Injury. Journal of Neurotrauma, 2019, 36, 1804-1817.	1.7	28
147	How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. European Journal of Haematology, 2019, 102, 36-52.	1.1	41
148	Complement-Mediated Coagulation Disorders. , 2019, , 473-490.		0
149	Budd-Chiari Syndrome. , 2020, , .		2
150	Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria. BioDrugs, 2020, 34, 149-158.	2.2	16
151	An inhibitor of complement C5 provides structural insights into activation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 362-370.	3.3	27
152	Successful treatment of a PNH patient nonâ€responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan). British Journal of Haematology, 2020, 188, 334-337.	1.2	21

#	Article	IF	Citations
153	Soluble Membrane Attack Complex: Biochemistry and Immunobiology. Frontiers in Immunology, 2020, 11, 585108.	2.2	34
154	Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation. Frontiers in Immunology, 2020, 11, 1460.	2.2	14
155	Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria. Hematology, Transfusion and Cell Therapy, 2021, 43, 341-348.	0.1	14
156	Ravulizumab in the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opinion on Orphan Drugs, 2020, 8, 257-264.	0.5	1
157	Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. Pharmaceuticals, 2020, 13, 341.	1.7	15
158	Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era. Nephron, 2020, 144, 537-549.	0.9	26
159	Pharmacogenetic and pharmaco-miR biomarkers for tailoring and monitoring myasthenia gravis treatments. Expert Review of Precision Medicine and Drug Development, 2020, 5, 317-329.	0.4	2
160	Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients. International Journal of Hematology, 2020, 112, 466-476.	0.7	5
161	Monoclonal Antibody-Based Therapies for Myasthenia Gravis. BioDrugs, 2020, 34, 557-566.	2.2	22
162	Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Frontiers in Immunology, 2020, 11, 599417.	2.2	31
163	Identification of acquired PIGA mutations and additional variants by nextâ€generation sequencing in paroxysmal nocturnal hemoglobinuria. International Journal of Laboratory Hematology, 2020, 42, 473-481.	0.7	8
164	Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?. Kidney International, 2020, 97, 1106-1108.	2.6	8
165	Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes. Blood Advances, 2020, 4, 2049-2057.	2.5	10
166	Characterizing the original antiâ€C5 functionâ€blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology, 2020, 161, 103-113.	2.0	11
167	Complement Inhibitor Therapy for Myasthenia Gravis. Frontiers in Immunology, 2020, 11, 917.	2.2	39
168	Paroxysmal nocturnal hemoglobinuria: Test to monitor the action of eculizumab treatment. International Journal of Laboratory Hematology, 2020, 42, 335-340.	0.7	1
169	Tackling COVIDâ€19 infection through complementâ€targeted immunotherapy. British Journal of Pharmacology, 2021, 178, 2832-2848.	2.7	39
170	Late renal recovery after treatment over 1â€‰year post-onset in an atypical hemolytic uremic syndrome: a case report. BMC Nephrology, 2020, 21, 236.	0.8	2

#	Article	IF	Citations
171	Eculizumab for the treatment of myasthenia gravis. Expert Opinion on Biological Therapy, 2020, 20, 991-998.	1.4	10
172	Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opinion on Biological Therapy, 2020, 20, 227-237.	1.4	15
173	A complementary new drug for PNH. Blood, 2020, 135, 884-885.	0.6	5
174	The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood, 2020, 135, 912-920.	0.6	73
175	Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642090420.	1.5	34
176	Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clinical Pharmacokinetics, 2021, 60, 365-378.	1.6	41
177	Update in immunosuppressive therapy of myasthenia gravis. Autoimmunity Reviews, 2021, 20, 102712.	2.5	38
178	Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opinion on Drug Safety, 2021, 20, 171-179.	1.0	9
179	The Benefits of Complement Measurements for the Clinical Practice. Methods in Molecular Biology, 2021, 2227, 1-20.	0.4	2
180	Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals, 2021, 14, 92.	1.7	35
181	MASPs at the crossroad between the complement and the coagulation cascades - the case for COVID-19. Genetics and Molecular Biology, 2021, 44, e20200199.	0.6	17
182	Diseases Associated With GPI Anchors. , 2021, , 346-363.		0
183	Targeting the complement system in neuromyelitis optica spectrum disorder. Expert Opinion on Biological Therapy, 2021, 21, 1073-1086.	1.4	33
184	Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties. Journal of Clinical Medicine, 2021, 10, 948.	1.0	7
186	Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacological Reviews, 2021, 73, 792-827.	7.1	97
187	Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor. American Journal of Hematology, 2021, 96, E232-E235.	2.0	10
188	Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibodyâ€“Positive Generalized Myasthenia Gravis. Expert Opinion on Investigational Drugs, 2021, 30, 483-493.	1.9	32
189	Complement testing in the clinical laboratory. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 447-478.	2.7	4

#	Article	IF	Citations
190	Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Multiple Sclerosis and Related Disorders, 2021, 50, 102849.	0.9	7
191	Avacopan for the treatment of ANCA-associated vasculitis. Expert Review of Clinical Immunology, 2021, 17, 717-726.	1.3	10
192	Halting targeted and collateral damage to red blood cells by the complement system. Seminars in Immunopathology, 2021, 43, 799-816.	2.8	11
193	Case Report: Lipoprotein Glomerulopathy Complicated by Atypical Hemolytic Uremic Syndrome. Frontiers in Medicine, 2021, 8, 679048.	1.2	3
194	How we(â€™ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. British Journal of Haematology, 2022, 196, 288-303.	1.2	27
195	Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children. Italian Journal of Pediatrics, 2021, 47, 181.	1.0	6
196	Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond. Blood, 2022, 139, 3571-3582.	0.6	33
197	Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. Frontiers in Immunology, 2021, 12, 712572.	2.2	41
198	Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine. Science Advances, 2021, 7, eabi6856.	4.7	16
199	Principles and Guidelines of Immunotherapy in Neuromuscular Disorders. , 2022, , 143-159.		0
200	Clinical Effects of Eculizumab in PNH: Extravascular Hemolysis After Eculizumab Treatment. , 2017, , 283-295.		1
201	The renaissance of complement therapeutics. Nature Reviews Nephrology, 2018, 14, 26-47.	4.1	305
202	A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic Syndrome. American Journal of Case Reports, 2016, 17, 950-956.	0.3	5
203	Complement Inhibition for the Treatment of Myasthenia Gravis . ImmunoTargets and Therapy, 2020, Volume 9, 317-331.	2.7	27
204	Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471). Current Medicinal Chemistry, 2020, 27, 4165-4180.	1.2	25
205	SKY59, A Novel Recycling Antibody for Complement-mediated Diseases. Current Medicinal Chemistry, 2020, 27, 4157-4164.	1.2	5
207	Complement-mediated haemolysis and the role of blood transfusion in paroxysmal nocturnal haemoglobinuria. Blood Transfusion, 2015, 13, 363-9.	0.3	6
208	Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Frontiers in Immunology, 2020, 11, 578069.	2.2	6

#	Article	IF	Citations
209	Complement involvement in kidney diseases: From physiopathology to therapeutical targeting. World Journal of Nephrology, 2015, 4, 169.	0.8	16
211	Genetic polymorphism in C5 and poor response to eculizumab. Japanese Journal of Thrombosis and Hemostasis, 2015, 26, 45-48.	0.1	0
212	TROMBINIÅ² MIKROANGIOPATIJÅ² SINDROMÅ² PATOGENETINIAI MECHANIZMAI, DIFERENCINÄ– DIAGNOSTIKA IR GYDYMAS. Medicinos Teorija Ir Praktika, 2015, 21, 675-682.	0.0	0
213	Complement in hemolytic anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 385-391.	0.9	0
215	Clinical Significance of Complement Abnormalities. , 2016, , 504-512.		0
216	Future Strategies of Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria. , 2017, , 319-346.		0
217	Clinical Effects of Eculizumab in PNH. , 2017, , 271-282.		0
218	Clinical Management in PNH. , 2017, , 253-269.		0
220	Liver Transplantation for Monogenic Metabolic Diseases Involving the Kidney. Journal of Renal and Hepatic Disorders, 2017, 1, 29-40.	0.1	0
221	Background and Presentation of Thrombotic Thrombocytopenic Purpura. , 2018, , 153-169.		0
222	Hemolytic Uremic Syndrome, Genetic. , 2018, , 1-13.		0
223	Ã‡ocukluk Ã‡aÄŸÄ±nda Atipik Hemolitik Üremik Sendrom. Dicle Medical Journal, 2018, 45, 491-501.	0.2	0
224	Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia: Challenges, Characteristics, and Analysis of Clinical Experience. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2019, 12, 319-328.	0.1	3
226	Buddâ€“Chiari Syndrome and Paroxysmal Nocturnal Hemoglobinuria. , 2020, , 89-105.		0
227	Treatment Options in Patients Suffering from Hemolytic-Uremic Syndrome: The Serbian Military Medical Academy Experience. Serbian Journal of Experimental and Clinical Research, 2022, 23, 237-242.	0.2	0
229	10. Complement and Diseases-what Physicians Should Know. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 1925-1931.	0.0	0
230	The emerging role of complement in neuromuscular disorders. Seminars in Immunopathology, 2021, 43, 817-828.	2.8	9
231	How Structures of Complement Complexes Guide Therapeutic Design. Sub-Cellular Biochemistry, 2021, 96, 273-295.	1.0	0

#	Article	IF	Citations
232	Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. Journal of Managed Care & Specialty Pharmacy, 2020, 26, S8-S14.	0.5	8
233	Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs. Journal of Managed Care & Specialty Pharmacy, 2020, 26, S14-S20.	0.5	8
234	Endplattenerkrankungen. , 2020, , 89-112.		0
235	Innovative Therapeutic Strategies in the Molecular Targeting Era. Current Medicinal Chemistry, 2020, 27, 4155-4156.	1.2	0
236	Biotechnological products for the treatment of complement system disorders including paroxysmal nocturnal hemoglobinuria: currently available and in development. Pediatric Hematology/Oncology and Immunopathology, 2020, 19, 164-172.	0.1	0
237	A Hispanic female patient with heartburn: A rare presentation of Paroxysmal Nocturnal Hemoglobinuria. BoletÃn De La AsociaciÃ³n MÃ©dica De Puerto Rico, 2015, 107, 9-12.	0.2	0
238	Eculizumab treatment for myasthenia gravis subgroups: 2021 update. Journal of Neuroimmunology, 2022, 362, 577767.	1.1	4
239	Pegcetacoplan for refractory paroxysmal nocturnal haemoglobinuria associated with the C5 genetic variant. British Journal of Haematology, 2021, , .	1.2	5
240	Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opinion on Emerging Drugs, 2022, 27, 33-43.	1.0	5
241	Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurology, The, 2022, 21, 189-202.	4.9	41
242	Rare Presentation of Atypical Hemolytic Uremic Syndrome in a Child With Acute Lymphocytic Leukemia and Pancreatitis. Journal of Pediatric Hematology/Oncology, 2022, Publish Ahead of Print, .	0.3	1
243	Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica, 2022, 107, 1483-1488.	1.7	5
244	A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies. Journal of Neuroscience Methods, 2022, 373, 109551.	1.3	6
245	Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1343-1351.	0.9	2
246	Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. Autoimmunity Reviews, 2022, 21, 103104.	2.5	7
247	Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan. Nephrology Dialysis Transplantation, 2023, 38, 414-424.	0.4	6
248	Novel and investigational therapies for wet and dry age-related macular degeneration. Drug Discovery Today, 2022, 27, 2322-2332.	3.2	31
258	Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis. Renal Failure, 2022, 44, 714-723.	0.8	8

#	Article	IF	Citations
259	Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria. Expert Review of Hematology, 2022, , 1-8.	1.0	2
260	The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. Therapeutic Advances in Hematology, 2022, 13, 204062072210910.	1.1	10
261	Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement <scp>C5</scp> polymorphism: Subanalysis of the phase 1/2 <scp>COMPOSER</scp> study. British Journal of Haematology, 2022, 198, .	1.2	4
262	Managing Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Patient-Focused Perspective. Journal of Blood Medicine, 0, Volume 13, 327-335.	0.7	6
263	Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PLoS ONE, 2022, 17, e0269749.	1.1	7
264	Novel Complement C5 Small-interfering RNA Lipid Nanoparticle Prolongs Graft Survival in a Hypersensitized Rat Kidney Transplant Model. Transplantation, 2022, 106, 2338-2347.	0.5	6
265	Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls. Seminars in Immunology, 2022, 59, 101618.	2.7	9
266	Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review. Therapeutics and Clinical Risk Management, 0, Volume 18, 699-719.	0.9	2
267	Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition. New England Journal of Medicine, 2022, 387, 160-166.	13.9	28
269	Monoclonal antibody drugs for the treatment of multiple sclerosis and neuromyelitis optica spectrum disorder. Clinical and Experimental Neuroimmunology, 0, , .	0.5	0
270	II. Neuromyelitis Optica Spectrum Disorder. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 1568-1574.	0.0	0
271	The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments. Expert Review of Clinical Pharmacology, 2022, 15, 851-861.	1.3	4
272	Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Frontiers in Immunology, 0, 13, .	2.2	1
273	Haemolytic uraemic syndrome. Lancet, The, 2022, 400, 1722-1740.	6.3	19
274	Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. Immunological Reviews, 2023, 313, 402-419.	2.8	10
275	Identification of potent siRNA targeting complement C5 and its robust activity in pre-clinical models of myasthenia gravis and collagen-induced arthritis. Molecular Therapy - Nucleic Acids, 2023, 31, 339-351.	2.3	3
276	The Japanese clinical guidelines 2022 for myasthenia gravis and Lambertâ€“Eaton myasthenic syndrome. Clinical and Experimental Neuroimmunology, 2023, 14, 19-27.	0.5	10
277	Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future. Paediatric Drugs, 2023, 25, 193-202.	1.3	4

#	Article	IF	Citations
278	Rare germline complement factor H variants in patients with paroxysmal nocturnal hemoglobinuria. Blood, 2023, 141, 1812-1816.	0.6	4
279	Paroxysmal nocturnal hemoglobinuria: Where we stand. American Journal of Hematology, 2023, 98, .	2.0	3
280	Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics, 2023, 24, 350-362.	7.7	46
281	The longâ€acting <scp>antiâ€C5</scp> ravulizumab results in <scp>C3</scp> binding to <scp>PNH</scp> red cells similar to its parental molecule eculizumab. British Journal of Haematology, 2023, 201, .	1.2	3
282	Complement biology for hematologists. American Journal of Hematology, 2023, 98, .	2.0	6
283	Mitigating Drugâ€“Targetâ€“Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors. Clinical Pharmacology and Therapeutics, 2023, 113, 904-915.	2.3	0
284	<scp>Longâ€term</scp> outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a <scp>realâ€world</scp> setting. European Journal of Haematology, 2023, 111, 84-95.	1.1	3
285	Reeling in complement in transplantâ€associated thrombotic microangiopathy: You're going to need a bigger boat. American Journal of Hematology, 2023, 98, .	2.0	1
287	Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH. Journal of Blood Medicine, 0, Volume 14, 239-245.	0.7	1
288	Atypical Hemolytic Uremic Syndrome. , 2023, , 605-639.		0
289	PNH and complement gene variants. Blood, 2023, 141, 1780-1782.	0.6	0
290	Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations. Advances in Therapy, 0, , .	1.3	2
291	Characterization of multivalent complexes formed in the presence of more than one conventional antibody to terminal complement component C5. PLoS ONE, 2023, 18, e0284502.	1.1	1
303	A guide to complement biology, pathology and therapeutic opportunity. Nature Reviews Immunology, 2024, 24, 118-141.	10.6	7
304	Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) â€“ revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology, 2024, 271, 141-176.	1.8	6
307	Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatric Nephrology, 0, , .	0.9	0
315	Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nature Reviews Neurology, 2024, 20, 84-98.	4.9	4
322	Myasthenia gravisâ€”Pathophysiology, diagnosis, and treatment. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 283-305.	1.0	0